Text Size

Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00383903
First received: October 3, 2006
Last updated: January 30, 2013
Last verified: January 2013
History of Changes
  Purpose

The purpose of this study is to determine the appropriate regimen of GSK HRV vaccine for concomitant administration with EPI vaccines to infants in South Africa.


Condition Intervention Phase
Rotavirus Gastroenteritis
 Biological: HRV vaccine
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: A Phase II, Randomized, Double-blind, Placebo-controlled Study of Safety, Reactogenicity and Immunogenicity of 2 or 3 Doses of GSK Bios' Oral Live Attenuated Human Rotavirus Vaccine at 106.5 CCID50 Viral Concentration in Healthy Infants (Approximately 5-10 Weeks Old) in the Republic of South Africa

Resource links provided by NLM:

MedlinePlus related topics: Gastroenteritis
U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Seroconversion after HRV vaccination [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • shedding, serum anti-rota IgA antibody concentrations, anti-polio 1, 2 and 3 seroprotection rates, reactogenicity, safety [ Designated as safety issue: No ]

Enrollment: 472
Study Start Date: September 2003
Study Completion Date: September 2004
Primary Completion Date: September 2004 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: HRV vaccine
    Two or three oral doses
  Eligibility

Ages Eligible for Study:   5 Weeks to 10 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy infants born after a normal gestation period (>=36 weeks), between 5 and 10 weeks of age at Dose 1 with confirmed negative HIV status of the subject's mother.
  • Written informed consent was obtained from the parent/guardian of the subject before study entry.

Exclusion Criteria:

  • History of allergic disease/polio disease,
  • Confirmed or suspected immunosuppressive or immunodeficient condition,
  • Clinically significant history of chronic gastrointestinal disease or other serious medical condition as determined by the investigator,
  • Received treatment prohibited by the protocol.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00383903

Locations
South Africa
GSK Investigational Site
Brits, South Africa, 0250
GSK Investigational Site
Ga-Rankuwa, South Africa, 0208
GSK Investigational Site
Pretoria, South Africa, 2
GSK Investigational Site
Pretoria North, South Africa, 2
GSK Investigational Site
Rooihuiskraal, South Africa, 0145
GSK Investigational Site
Sunnyside, Pretoria, South Africa, 2
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00383903     History of Changes
Other Study ID Numbers: 444563/013
Study First Received: October 3, 2006
Last Updated: January 30, 2013
Health Authority: South Africa: Medicines Control Council

Additional relevant MeSH terms:
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on June 18, 2013